AbbVie pays Gubra $350M to make late play for obesity space
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra.
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra.
